Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ART-123 in severe sepsis with coagulopathy
MOH_2017-08-29_000769Phase 3Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Feb 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and coagulopathy comparing ART-123 with Placebo (2 arms). Started Feb 2013; status: completed.
02
Drugs
thrombomodulin alfa
03
Conditions
sepsiscoagulopathy
Beyond the preview
Go deeper on MOH_2017-08-29_000769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-29_000769.